Beacon Crc: a Randomized, Phase 3 Study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BiNI) vs. Choice of Either Irinotecan or Folfiri Plus Cetux in BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC)

Arndt Vogel, Susanna Hegewisch-Becker, Gerald Prager, Gunnar Folprecht, Michael Stahl, Scott Kopetz, Axel Grothey, Eric van Cutsetn, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardello, Ashwin Gollerkeri, Kati Maharry, Fotios Loupakis, Y Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik-Tobias Arkenau Show all